GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » ROA %

Akoya Biosciences (Akoya Biosciences) ROA % : -56.06% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Akoya Biosciences's annualized Net Income for the quarter that ended in Mar. 2024 was $-93.94 Mil. Akoya Biosciences's average Total Assets over the quarter that ended in Mar. 2024 was $167.56 Mil. Therefore, Akoya Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 was -56.06%.

The historical rank and industry rank for Akoya Biosciences's ROA % or its related term are showing as below:

AKYA' s ROA % Range Over the Past 10 Years
Min: -39.74   Med: -31.97   Max: -16.5
Current: -39.74

During the past 5 years, Akoya Biosciences's highest ROA % was -16.50%. The lowest was -39.74%. And the median was -31.97%.

AKYA's ROA % is ranked worse than
77.14% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: -2.055 vs AKYA: -39.74

Akoya Biosciences ROA % Historical Data

The historical data trend for Akoya Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akoya Biosciences ROA % Chart

Akoya Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
-16.50 -20.00 -31.97 -38.50 -35.53

Akoya Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.54 -48.50 -28.22 -24.16 -56.06

Competitive Comparison of Akoya Biosciences's ROA %

For the Medical Instruments & Supplies subindustry, Akoya Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akoya Biosciences's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Akoya Biosciences's ROA % falls into.



Akoya Biosciences ROA % Calculation

Akoya Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-63.323/( (176.031+180.369)/ 2 )
=-63.323/178.2
=-35.53 %

Akoya Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-93.936/( (180.369+154.75)/ 2 )
=-93.936/167.5595
=-56.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


Akoya Biosciences  (NAS:AKYA) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-93.936/167.5595
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-93.936 / 73.4)*(73.4 / 167.5595)
=Net Margin %*Asset Turnover
=-127.98 %*0.4381
=-56.06 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Akoya Biosciences ROA % Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akoya Biosciences (Akoya Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.
Executives
Brian Mckelligon director, officer: President/CEO 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla officer: Chief Operating Officer C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler director C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin director, 10 percent owner C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler director
Jennifer Kamocsay officer: General Counsel 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll officer: Chief Financial Officer 5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d. director 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler director 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry officer: Chief Medical Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy officer: Chief People Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d officer: Chief Business Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752